Histogenics Says More Data from Human Engineered Cartilage Testing Support Potential BLA for NeoCart

Histogenics (HSGX) said late Monday that the additional biomechanical data from human engineered cartilage testing will be used to support its a potential biologics license application with the U.S. Food and Drug Administration for NeoCart, a cartilage-like, tissue engineered implant created from a patient’s own cartilage cells.

The company said the study analyzes the compressive properties of engineered cartilage tissue grown with chondrocytes seeded in a porous scaffold based on work completed as part of a sponsored research agreement between Histogenics and Lawrence Bonassar of Cornell University.

“These data add to the strong body of evidence demonstrating that our combination of cells, scaffold and tissue engineering which produces cartilage tissue ex vivo are critical for these therapies to function properly upon implantation in the body,” Chief Technology Officer Stephen Kennedy said. “We believe that NeoCart is unique in exhibiting these characteristics prior to implantation and are confident that this is one of the reasons we have seen such early preliminary recovery from pain and return to function as demonstrated by the data from the phase 1 and 2 clinical trials of NeoCart.”

Leave a Comment